The post Ethereum (ETH) Price Analysis for December 4 appeared on BitcoinEthereumNews.com. The market is mainly green today, according to CoinStats. ETH chart by CoinStats ETH/USD Ethereum (ETH) is one of the biggest gainers today, rising by 3.77%. Image by TradingView On the hourly chart, the rate of ETH might have set a local support of $3.158. If the daily bar closes near that mark, the decline is likely to continue to the $3,100 range. Image by TradingView On the longer time frame, the price of the main altcoin has once again failed to fix above the $3,230 level.  You Might Also Like If the candle closes far from that mark, bears may seize the initiative, which may lead to a test of the $3,100 zone by the end of the week. Image by TradingView From the midterm point of view, one should focus on the weekly bar’s closure in terms of the $3,233 level. If bulls can hold the gained initiative and the candle closes around that mark, or above, the accumulated energy might be enough for a continued upward move to the $3,300-$3,400 range. Ethereum is trading at $3,155 at press time. Source: https://u.today/ethereum-eth-price-analysis-for-december-4The post Ethereum (ETH) Price Analysis for December 4 appeared on BitcoinEthereumNews.com. The market is mainly green today, according to CoinStats. ETH chart by CoinStats ETH/USD Ethereum (ETH) is one of the biggest gainers today, rising by 3.77%. Image by TradingView On the hourly chart, the rate of ETH might have set a local support of $3.158. If the daily bar closes near that mark, the decline is likely to continue to the $3,100 range. Image by TradingView On the longer time frame, the price of the main altcoin has once again failed to fix above the $3,230 level.  You Might Also Like If the candle closes far from that mark, bears may seize the initiative, which may lead to a test of the $3,100 zone by the end of the week. Image by TradingView From the midterm point of view, one should focus on the weekly bar’s closure in terms of the $3,233 level. If bulls can hold the gained initiative and the candle closes around that mark, or above, the accumulated energy might be enough for a continued upward move to the $3,300-$3,400 range. Ethereum is trading at $3,155 at press time. Source: https://u.today/ethereum-eth-price-analysis-for-december-4

Ethereum (ETH) Price Analysis for December 4

For feedback or concerns regarding this content, please contact us at [email protected]

The market is mainly green today, according to CoinStats.

ETH chart by CoinStats

ETH/USD

Ethereum (ETH) is one of the biggest gainers today, rising by 3.77%.

Image by TradingView

On the hourly chart, the rate of ETH might have set a local support of $3.158. If the daily bar closes near that mark, the decline is likely to continue to the $3,100 range.

Image by TradingView

On the longer time frame, the price of the main altcoin has once again failed to fix above the $3,230 level. 

You Might Also Like

If the candle closes far from that mark, bears may seize the initiative, which may lead to a test of the $3,100 zone by the end of the week.

Image by TradingView

From the midterm point of view, one should focus on the weekly bar’s closure in terms of the $3,233 level. If bulls can hold the gained initiative and the candle closes around that mark, or above, the accumulated energy might be enough for a continued upward move to the $3,300-$3,400 range.

Ethereum is trading at $3,155 at press time.

Source: https://u.today/ethereum-eth-price-analysis-for-december-4

Market Opportunity
Ethereum Logo
Ethereum Price(ETH)
$1,987.28
$1,987.28$1,987.28
+0.45%
USD
Ethereum (ETH) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09